Novo Nordisk announced layoffs of 4,000 employees on September 21, 2026. Novo told its London capital markets day that cuts had reached 13,000 positions, about 4,000 more than the 9,000 it announced in 2025. Competition in the obesity drug market drove the deeper reduction.